ReWalk Robotics Reports Third Quarter

ReWalk Robotics Reports Third Quarter

2018 Financial Results

- Total revenue of $1.6 million during the third quarter of 2018 -

- Recruitment completed for the ReStore soft exo-suit clinical study -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 8, 2018

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced its financial

results for the three and nine months ended September 30, 2018.

Highlights of and subsequent to the third quarter include:

has made significant progress to advance our R&D efforts for ReStore and support reimbursement. Positive developments with

insurance providers in both the U.S. and Germany suggest we should see increased coverage for the ReWalk exoskeleton for SCI patients

as we end 2018 and head into 2019. We have applied for CE mark clearance; and, with our ReStore study enrollment near completion,

we are on track to file with the FDA by year end 2018 or early 2019, positioning us to potentially have a stroke product on the

market in the U.S. in Q3 2019. We continue to explore all financing options available to the Company in order to ensure that we

are able to execute our strategy and advance our important products for the SCI and stroke communities," stated Larry

Jasinski, Chief Executive Officer of ReWalk.

Third Quarter 2018 Financial

Total revenue was $1.6 million for

the third quarter of 2018, compared to $1.8 million in the second quarter of 2018 and $1.7 million during the prior year quarter.

22 ReWalk systems were placed during the third quarter of 2018, compared to 21 ReWalk systems placed in the prior quarter and 16

systems in the prior year period. 11 systems were placed in the U.S., 9 were placed in our direct markets in Europe and an additional

2 were placed in other markets.

Gross margin improved to 47% during

the third quarter of 2018 compared to 41% in the third quarter of 2017, primarily attributable to sales mix and lower product costs.

Total operating expenses in the third

quarter of 2018 were $4.9 million compared to $6.1 million in the prior year period.

Net loss was $4.5 million for the third

quarter of 2018 compared to a net loss of $5.8 million in the third quarter of 2017. Non-GAAP net loss for the third quarter was

$3.8 million compared with a non-GAAP net loss of $4.8 million in the third quarter of 2017. A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

As of September 30, 2018, ReWalk had

$5.2 million in cash on its balance sheet.

The Company is updating its full year

2018 revenue guidance and now expects revenues to reach between $7 million and $8 million.

ReWalk management will host its third

quarter 2018 conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 6559929.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation

and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel and the United States.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include

projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's expectations regarding future growth, including its ability to increase sales

in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of

ReWalk's management and the previous opinion of ReWalk's auditors in that there are substantial doubts as to ReWalk's

ability to continue as a going concern; ReWalk's ability to regain compliance with the continued listing requirements of

the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's ability to

maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from

third-party payors for its products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's

expectations as to the results of, and the Food and Drug Administration's potential regulatory developments with respect

to, ReWalk's mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating

to ReWalk's initial public offering; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to

improve its products and develop new products; the risk that the remaining Timwell Corporation Limited ("Timwell")

issuances will fail to close and the China joint venture will not form, and the resulting effect on ReWalk's liquidity and

financial condition; the risk of substantial dilution resulting from additional issuances, if any, to Timwell; the significant

voting power and de facto voting control Timwell may acquire upon additional issuances, if any; ReWalk's ability to maintain

adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's

ability to gain and maintain regulatory approvals; ReWalk's ability to secure capital from its equity and debt financings

in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and

the risk that such financings may dilute ReWalk's shareholders or restrict its business; ReWalk's ability to use effectively

the proceeds of offerings of securities; the impact of the market price of ReWalk's ordinary shares on the determination

of whether ReWalk is a passive foreign investment company; ReWalk's ability to maintain relationships with existing customers

and develop relationships with new customers; ReWalk's compliance with medical device reporting regulations to report adverse

events involving its products and the potential impact of such adverse events on ReWalk's ability to market and sell its

products; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K

for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the "SEC") and

other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks

only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained

herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk

undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three- and nine-months ended September 30, 2018 and

2017, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation

and (iii) non-cash financial expenses.

Because of varying available valuation

methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses,

ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense, depreciation

and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period to period.

Each of the Company's non-GAAP financial measures is an important tool for financial and operational decision-making and

for the Company's evaluation of its operating results over different periods of time. The non-GAAP financial data are not